Lexicon Pharmaceuticals, Inc.
sotagliflozin
type 1 diabetes
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on sotagliflozin for type 1 diabetes is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“Based on current STENO1 enrollment estimates, the Company is preparing to potentially resubmit the NDA in 2026 if supported by patient exposure and safety data from STENO1.”